Brischetto et al., 2020 - Google Patents
Testing for COVID-19Brischetto et al., 2020
View HTML- Document ID
- 17764501161722129340
- Author
- Brischetto A
- Robson J
- Publication year
- Publication venue
- Australian Prescriber
External Links
Snippet
Testing for COVID-19 - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview improvements
coming to the PMC website in October 2024. Learn More or Try it out now. Search PMC …
- 200000000015 coronavirus disease 2019 0 title abstract description 22
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—AIDS or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scohy et al. | Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis | |
Lai et al. | Laboratory testing for the diagnosis of COVID-19 | |
World Health Organization | Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief, 8 April 2020 | |
Zhang et al. | Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing | |
Cho et al. | Evaluation of five rapid diagnostic kits for influenza A/B virus | |
Aoki et al. | Evaluation of clinical utility of novel coronavirus antigen detection reagent, Espline® SARS-CoV-2 | |
Lim et al. | Current laboratory diagnosis of coronavirus disease 2019 | |
Bailey et al. | Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology | |
Jia et al. | False negative RT-PCR and false positive antibody tests–concern and solutions in the diagnosis of COVID-19 | |
Abusrewil et al. | Time scale performance of rapid antigen testing for SARS‐CoV‐2: Evaluation of 10 rapid antigen assays | |
Brischetto et al. | Testing for COVID-19 | |
Gulholm et al. | Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 | |
Verma et al. | Rapid diagnostic methods for SARS-CoV-2 (COVID-19) detection: an evidence-based report | |
Flores et al. | Performance of ANTI‐HCV testing in dried blood spots and saliva according to HIV status | |
Randriamahazo et al. | Evaluation of antigen-based rapid detection test for the diagnosis of SARS CoV-2 in low-income countries | |
Zhou et al. | A preliminary study on analytical performance of serological assay for SARS-CoV-2 IgM/IgG and application in clinical practice | |
Lei et al. | Different methods of COVID-19 detection | |
Parikh et al. | Laboratory evaluation of SARS-CoV-2 in the COVID-19 pandemic | |
Sidiq et al. | Laboratory diagnosis of novel corona virus (2019-nCoV)-present and the future | |
Wang et al. | Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients | |
Al-Alawi et al. | Evaluation of four rapid antigen tests for detection of SARS-CoV-2 virus | |
Lapić et al. | The reliability of SARS-CoV-2 IgG antibody testing–a pilot study in asymptomatic health care workers in a Croatian university hospital | |
Mannan et al. | Detection of SARS-CoV-2 RNA by reverse transcription-polymerase chain reaction (RT-PCR) on self-collected nasal swab compared with professionally collected nasopharyngeal swab | |
Al-Ibraheemi et al. | The relationship between IgG and IgM levels and severity of symptoms in COVID-19 patients confirmed by rapid antigen test | |
Dörschug et al. | Evaluation of the Xiamen AmonMed Biotechnology rapid diagnostic test COVID-19 IgM/IgG test kit (Colloidal gold) |